Adult patients with HER2-low (IHC 1+ or IHC 2+/ISH) metastatic or unresectable breast cancer who previously had chemotherapy in a metastatic context or who have experienced a disease recurrence while receiving adjuvant chemotherapy or within 6 months of finishing it. Here, ERBB2 is linked to breast carcinoma.